| In a significant advancement, Indaptus Therapeutics (Nasdaq: INDP) has officially initiated its Phase 1b/2 combination trial evaluating Decoy20 alongside BeiGene’s PD-1 checkpoint inhibitor, tislelizumab.
This expansion represents a critical milestone, as it transitions from pre-clinical validation into real-world patient testing.
Why This Matters:
- Expands clinical opps. for Decoy20 in multiple cancer types.
- Tests Decoy20’s synergy with checkpoint inhibitors—a strategy that could enhance treatment response and durability.
- Represents a key moment for Indaptus, advancing from pre-clinical promise into patient-focused validation.
Trial Design & Objectives:
- Patients will first receive one week of Decoy20 monotherapy before initiating combination therapy.
- Early participants will be monitored sequentially for safety before transitioning into broader patient enrollment upon Safety Review Committee approval.
- Participants may continue treatment for up to one year, or until disease progression, unacceptable toxicity, or withdrawal.
Jeffrey Meckler, CEO of Indaptus Therapeutics, Inc. (Nasdaq: INDP), highlighted the significance of this milestone, stating:
“This marks a pivotal step forward for Indaptus and our Decoy platform. Preclinical research has consistently shown that Decoy20 works synergistically with a checkpoint inhibitor, and we now have the opps. to test that in patients for the first time. While this initial phase will focus on safety and tolerability, we are laying the groundwork for what could be a game-changing approach to treating solid tumors.”
Checkpoint inhibitors, like tislelizumab, have transformed cancer treatment, but many patients still do not respond or experience disease progression.
Decoy20 is engineered to enhance the immune system’s response, potentially broadening checkpoint inhibitor effectiveness and delivering longer-lasting tumor control.
With the launch of this combination trial, Indaptus is taking a major step forward in demonstrating Decoy20’s full potential—not only as a monotherapy but as a cornerstone in next-generation immunotherapy combinations.
Expanding Intellectual Property Portfolio: Strengthening Long-Term Value
A strong intellectual property (IP) portfolio is critical in biotechnology, and Indaptus Therapeutics (Nasdaq: INDP) continues to reinforce its leadership position through patent expansion.
Recent IP Milestones:
- New patents granted in China, Japan, and Israel, covering Decoy bacteria compositions for treating Hepatitis B (HBV) and HIV.
- Patent protection strengthens Indaptus' leadership in bacterial-based immunotherapies.
- Opens potential commercialization opps. in major global markets.
By securing patents in key international markets, Indaptus is positioning itself for long-term success and potential future licensing opps.
Fiscal Strength & Growth Outlook
Indaptus Therapeutics (Nasdaq: INDP) has demonstrated financial discipline, ensuring that it can continue advancing its clinical programs while maintaining operational efficiency.
Highlights (FY 2024):
- $5.8M in ca-sh and ca-sh equivalents as of December 31, 2024.
- Completed multiple fin-anc-ings, including registered direct offerings and an equity line, providing financial flexibility.
- Established a $20M equity line of cre-dit with Yorkville, extending Indaptus' financial runway into Q2 2025.
By strategically managing its resources, Indaptus remains well-positioned to continue advancing its clinical pipeline and executing on its corporate strategy. What’s Next? A Look Ahead at 2025
With multiple near-term potential catalysts on the horizon, 2025 could be a transformational year for Indaptus.
Key 2025 Milestones to Watch:
- Dosing of the first patients in the Decoy20 + tislelizumab combination study.
- Expansion of clinical trial sites, accelerating patient enrollment and data collection.
- Additional data readouts from the Phase 1 trial, further refining Decoy20’s safety and efficacy profile.
- Potential nomination of a new Decoy platform candidate for IND-enabling studies.
With multiple near-term inflection points, Indaptus Therapeutics (Nasdaq: INDP) is entering a pivotal phase of growth, setting the stage for its long-term impact in oncology and infectious disease immunotherapy.
7 Reasons Why Indaptus Therapeutics (Nasdaq: INDP) is Topping Our Watchlist This Morning…
1. Analyst Coverage: In a report published on March 14, 2025, Indaptus Therapeutics (Nasdaq: INDP) was listed as having a $5 target by Maxim Group analyst Jason McCarthy, Ph.D., which suggests over 437% upside potential from its $0.931 opening yesterday.
2. Low Float & Market Cap: With a market cap under $13M and a float of approximately 12M shares, Indaptus Therapeutics (Nasdaq: INDP) has the type of structure where volatility could become a key factor if more attention builds.
3. Advancing Immunotherapy Innovation: A next-generation immunotherapy approach is taking shape with the Decoy platform, a technology designed to stimulate both innate and adaptive immune responses—a fundamental advancement being pursued by Indaptus Therapeutics, Inc. (Nasdaq: INDP).
4. Key Clinical Trial Milestone: A Phase 1b/2 combination trial has now officially begun, testing Decoy20 alongside BeiGene’s PD-1 checkpoint inhibitor, tislelizumab, marking a critical step forward in the clinical pipeline for Indaptus Therapeutics, Inc. (Nasdaq: INDP).
5. Expanding Intellectual Property: New patents covering Decoy bacteria compositions for Hepatitis B (HBV) and HIV have been granted in China, Japan, and Israel, further strengthening the position of Indaptus Therapeutics (Nasdaq: INDP) in bacterial-based immunotherapy.
6. Strong Fiscal Positioning: As of December 31, 2024, reported ca-sh holdings stood at $5.8M, while a newly established $20M equity line with Yorkville provides extended flexibility for Indaptus Therapeutics (Nasdaq: INDP) into Q2 2025.
7. Multiple Upcoming Catalysts: A series of anticipated milestones in 2025—including new clinical data releases, trial site expansions, and the potential nomination of another Decoy platform candidate—are all developments to watch for Indaptus Therapeutics, Inc. (Nasdaq: INDP).
Put Indaptus Therapeutics (Nasdaq: INDP) on Your Radar for This Morning…
Some things don’t stay under the radar forever, and Indaptus Therapeutics (Nasdaq: INDP) has too many factors lining up to be ignored for long.
With a $5 target from Maxim Group, a small float under 12M shares, and a market cap barely scratching $13M—that’s the kind of equation that can get interesting fast.
Add to that a Phase 1b/2 trial now in motion with a major player, fresh patents secured across multiple countries, and strong positioning heading into 2025, and it’s clear why attention could start shifting here.
We have all eyes on (INDP) this morning.
Consider taking a look at (INDP) while it’s still early–and remember to do your own research. As momentum potential continues to build, with (INDP) moving approximately 13% to $.92 in early session—we have this one at the top of our screens.
Remember, after yesterday’s approx. 82% swing from $0.93 to $1.70, we’re watching (INDP) like a hawk.
Indaptus Therapeutics (Nasdaq: INDP) is now lighting up 16 Bullish Signals on TradingView’s technical analysis tool using the 1 minute time-frame.
If you haven’t pulled up (INDP), now might be a good time.
And please keep your eyes peeled for my next update—I don’t want you to miss anything. | 
No comments:
Post a Comment